LALuisa Alvarez

Luisa Alvarez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Luisa Alvarez has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment

    by L. Alvarez, P. Peris, N. Guañabens, S. Vidal, Ll. Quintó, A. Monegal, F. Pons, A. M. Ballesta, J. Muñoz-Gómez

    Objectives. To monitor the long-term evolution of Paget's disease activity after treatment with tiludronate by using serum total alkaline phosphatase (TAP) and more sensitive markers such as bone alkaline phosphatase (BAP), procollagen type I N propeptide (PINP) and urinary N-terminal cross-linking telopeptide of type I collagen (NTX); to analyse the predictors of long-term response to therapy; and to study the most appropriate intervals of time for monitoring the response to therapy.


  • Effect of hemodialysis and renal failure on serum biochemical markers of bone turnover

    by Luisa Alvarez, Jose-Vicente Torregrosa, Pilar Peris, Ana Monegal, Jose-Luis Bedini, Maria-Jesús Martinez De Osaba, Xavier Filella, Gloria Martin, Carmen Ricos, Federico Oppenheimer, et al.

    The aim of the present study was to evaluate the effect of hemodialysis and renal failure on serum bone markers. Serum total alkaline phosphatase (TAP), procollagen type I aminoterminal propeptide (PINP), and Β-carboxyterminal telopeptide of type I collagen (Β-CTX), as well as intact parathyroid hormone (iPTH), creatinine, and total protein were measured in 14 patients with endstage renal disease (ESRD) before and at 1, 2, and 4 h during a hemodialysis session, and at the same sampling interval in 6 renal transplant recipients. The results were compared to those obtained in 20 healthy adults. All patients showed increased baseline mean values of PINP, Β-CTX, and iPTH. Β-CTX differed significantly between hemodialysis patients and renal transplant recipients. TAP and Β-CTX were the only markers which correlated with iPTH (P ≪ 0.05) and creatinine values (P ≪ 0.001), respectively. Renal transplant recipients did not show significant variations in the evolution of mean values of bone markers throughout the study, whereas, during the dialysis period, all the bone markers analyzed in the study showed a significant change. The change differed depending on the marker considered: Β-CTX showed a significant decrease at the end of the session, TAP increased at this time and, although PINP showed an initial increase during hemodialysis, no significant changes were observed at the end of the session. We conclude that bone markers are significantly influenced by hemodialysis, especially serum TAP and Β-CTX. ESRD is associated with an increase in these bone markers, in some cases related to iPTH values and in others to glomerular function. These findings should be taken into account when evaluating bone markers in these patients.


  • Open Access

    Serum osteoprotegerin and its ligand in Paget's disease of bone: Relationship to disease activity and effect of treatment with bisphosphonates

    by L. Alvarez, P. Peris, N. Guañabens, S. Vidal, I. Ros, F. Pons, X. Filella, A. Monegal, J. Muñoz‐Gomez, A. M. Ballesta

    Objective: To test the following hypotheses: 1) osteoprotegerin (OPG) and receptor activator of nuclear factor κB ligand (RANKL) serum levels in patients with Paget's disease are related to disease activity and are different from those in healthy individuals; 2) interleukin‐6 (IL‐6), a cytokine that has been shown to have higher levels in Paget's disease, modulates these factors; and 3) the antiresorptive effect of bisphosphonates in Paget's disease of bone may be mediated through these local factors.Methods: The study group comprised 31 patients with Paget's disease who received 400 mg/day of oral tiludronate for 3 months. Serum levels of OPG, RANKL, IL‐6, bone alkaline phosphatase (AP), N‐terminal type I procollagen propeptide, urinary N‐terminal crosslinking telopeptide of type I collagen, and urinary α–C‐terminal crosslinking telopeptide of type I collagen were measured at baseline and 1 month after the end of therapy. In addition, the RANKL:OPG ratio was calculated, and disease activity was evaluated at baseline by quantitative bone scintigraphy.Results: Mean baseline OPG values were higher in patients with Paget's disease than in healthy control subjects (P < 0.005), but RANKL and IL‐6 values and RANKL:OPG ratios in the 2 groups were similar. OPG concentrations decreased significantly after treatment with tiludronate (P < 0.005), whereas no significant changes were observed in serum RANKL values. No correlation was found between either bone markers or quantitative scintigraphic indices and serum levels of OPG, RANKL, IL‐6, and RANKL:OPG ratios. Serum OPG decreased significantly only in those patients with baseline OPG values >4.1 pM/liter.Conclusion: Serum OPG increases in Paget's disease and decreases after treatment with tiludronate, especially in patients with the highest OPG values. In contrast, RANKL serum levels and RANKL:OPG ratios are unmodified in patients with Paget's disease. Although serum OPG, RANKL, and IL‐6 values were unrelated to disease activity, the increase in OPG may reflect a protective mechanism of the skeleton to compensate for increased bone resorption.


  • Usefulness of biochemical markers of bone turnover in assessing response to the treatment of paget’s disease

    by L Alvarez, N Guañabens, P Peris, S Vidal, I Ros, A Monegal, J.L Bedini, R Deulofeu, F Pons, J Muñoz-Gomez, et al.


  • Components of biological variation of biochemical markers of bone turnover in Paget’s bone disease

    by L. Alvarez, C. Ricós, P. Peris, N. Guañabens, A. Monegal, F. Pons, A.M. Ballesta


  • Open Access

    Collagen Type I α1 Gene Sp1 Polymorphism in Premenopausal Women with Primary Osteoporosis: Improved Detection of Sp1 Binding Site Polymorphism in the Collagen Type 1 Gene

    by Luisa Alvarez, Josep Oriola, Judith Jo, Teresa Ferró, Francesca Pons, Pilar Peris, Nuria GuañaBens, Magdalena Durán, Ana Monegal, M Jesús MartínEz de Osaba, et al.

    Osteoporosis is a common disorder characterized by reduced bone mass and increased risk of fracture (1). Evidence from family studies suggests that genetic factors have a major role in the determination of bone mass (2). Because bone mass and bone strength are complex phenotypes, their heredity is almost certainly polygenic. Among the potential candidate genes that might influence bone mass acquisition, special attention has been directed to the vitamin D receptor and estrogen receptor genes; results of these studies, however, have been contradictory (3)(4)(5). Type I collagen, a protein encoded by the collagen I α1 (COLIA1) and collagen I α2 (COLIA2) genes, is the major protein of bone matrix. Genes encoding collagen type I may be important candidates for the genetic regulation of bone density because mutations that affect their coding regions have been associated with osteogenesis imperfecta (6).